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Polycyclic aromatic hydrocarbons (PAHs) are
high-priority environmental contaminants
because of their toxic, carcinogenic, and puta-
tive estrogenic or antiestrogenic properties in
the human body. Human exposure to high-
molecular-weight PAHs mainly occurs
through oral uptake of charcoal-broiled,
grilled, and smoked meats (van Maanen et al.
1994) and through ingestion of soil or poorly
cleaned vegetables, resulting in exposed doses
about an order of magnitude higher than
exposure by inhalation (Heisterkamp and van
Veen 1997). The hazardous effects of ingested
PAHs come from the PAH fraction released
from the nutrients, soil, or associated organic
matter in the intestinal lumen and that, upon
intestinal absorption, reaches the intestine
enterocytes and liver hepatocytes. In these
cells, PAHs may act as ligands to the human
aryl hydrocarbon (Ah) receptor, which plays a
central role in the toxic response of specific
aromatic hydrocarbons by the regulation of
typical human biotransformation enzymes
(reviewed by Hankinson 1995).
The risk from orally ingested PAHs is cur-
rently thought to be reduced when co-ingested
soil or fibers decrease the intestinal PAH
absorption and hence bioavailability (De Kok
and van Maanen 2000). Most ingested PAHs
pass harmlessly through the gastrointestinal
(GI) tract without being transformed by
human enzymes to hazardous metabolites.
However, this assumes that no microbial bio-
transformation of PAHs occurs. The human
GI tract harbors an incredibly diverse micro-
bial community, which typically performs fer-
mentative processes but which is also capable
of transforming xenobiotic compounds (Aura
et al. 2002; Ilett et al. 1990; Macdonald et al.
1983). Hence, if microbial PAH bio-
transformation in the human colon is possi-
ble, the susceptibility of the colon epithelium
to bioactive PAH metabolites may increase
the health risks that are associated with non-
absorbed PAHs that reach the colon. To date,
no information is available on the PAH bio-
activation potency from human colon micro-
biota. To evaluate this, in this study we
investigated the estrogenicity of PAHs because
several PAH metabolites structurally resemble
steroidal hormones that bind the human
estrogen receptor (ER) (Ariese et al. 2001),
which could thus lead to estrogenic or anti-
estrogenic activity in vivo.
We opted for an in vitro approach to
speciﬁcally look for microbial biotransforma-
tions and thus avoid possible interference
from colon epithelium enzymes that would be
present in an in vivo approach. Pure PAH
compounds and a PAH-contaminated urban
soil were incubated in the stomach, small
intestine, and colon suspensions from a simu-
lator of the human GI tract. Given the aro-
maticity of PAHs, we used a modified Ah
receptor yeast assay (Miller 1997) to investi-
gate whether the PAHs in the different digests
could activate the human Ah receptor and
subsequently induce signal transduction. We
also investigated the estrogenicity of the PAH
incubated digests by monitoring activation of
the human ER in a modified ER yeast assay
(Routledge and Sumpter 1996). In addition,
we applied a newly optimized liquid chro-
matography–mass spectrometry (LC-MS)
protocol to detect whether PAH metabolites
were formed during incubation.
Materials and Methods
Chemicals. PAH parent compounds naphtha-
lene, phenanthrene, pyrene, and benzo(a)pyrene
(reagent grade) were obtained from Sigma-
Aldrich (Bornem, Belgium). To avoid solubil-
ity problems in the incubation tests, PAHs
were ﬁrst dissolved in ethanol before digestion.
All stock solutions were prepared in amber
glass bottles and stored in the dark at 4°C.
Hydroxy-PAH metabolites 1-OH naphtha-
lene, 9-OH phenanthrene, 1-OH pyrene, and
7-OH benzo(a)pyrene were reagent grade and
also obtained from Sigma-Aldrich.
Incubations. PAHs and soils were incu-
bated in batches by sampling GI suspensions
from a simulator of the human intestinal
microbial ecosystem (SHIME). This dynamic
model of the GI tract consists of five com-
partments representing the stomach, small
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Ingestion is an important exposure route for polycyclic aromatic hydrocarbons (PAHs) to enter
the human body. Although the formation of hazardous PAH metabolites by human biotrans-
formation enzymes is well documented, nothing is known about the PAH transformation potency
of human intestinal microbiota. Using a gastrointestinal simulator, we show that human intestinal
microbiota can also bioactivate PAHs, more in particular to estrogenic metabolites. PAH com-
pounds are not estrogenic, and indeed, stomach and small intestine digestions of 62.5 nmol naph-
thalene, phenanthrene, pyrene, and benzo(a)pyrene showed no estrogenic effects in the human
estrogen receptor bioassay. In contrast, colon digests of these PAH compounds displayed estro-
genicity, equivalent to 0.31, 2.14, 2.70, and 1.48 nmol 17α-ethynylestradiol (EE2), respectively.
Inactivating the colon microbiota eliminated these estrogenic effects. Liquid chromatography–
mass spectrometry analysis conﬁrmed the microbial PAH transformation by the detection of PAH
metabolites 1-hydroxypyrene and 7-hydroxybenzo(a)pyrene in colon digests of pyrene and
benzo(a)pyrene. Furthermore, we show that colon digests of a PAH-contaminated soil (simulated
ingestion dose of 5 g/day) displayed estrogenic activity equivalent to 0.58 nmol EE2, whereas
stomach or small intestine digests did not. Although the matrix in which PAHs are ingested may
result in lower exposure concentrations in the gut, our results imply that the PAH bioactivation
potency of colon microbiota is not eliminated by the presence of soil. Moreover, because PAH
toxicity is also linked to estrogenicity of the compounds, the PAH bioactivation potency of colon
microbiota suggests that current risk assessment may underestimate the risk from ingested PAHs.
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intestinal microbial ecosystem (SHIME). Environ Health Perspect 113:6–10 (2005).intestine, and colon ascendens, transversum,
and descendens (Figure 1). The colon suspen-
sion contains in vitro cultured microbiota that
were isolated from human feces and are repre-
sentative of the in vivo colon microbial ecology
after a growth stabilization period in the differ-
ent colon compartments (Molly et al. 1993). A
typical stomach digestion consists of an incu-
bation of PAHs or PAH-contaminated soil
samples for 3 hr at pH 1.5 at 37°C. A small
intestine digestion consists of an incubation for
5 hr at pH 7 at 37°C in the presence of bile
salts (0.2 mmol/L) and pancreatic enzymes
supplemented as pancreatic powder of porcine
origin (0.4 g/L). A colon digestion consists of
an incubation with colon microbiota for 48 hr
at 37°C, withdrawn from the colon vessels of
the SHIME reactor. Some samples were incu-
bated with inactive colon microbiota. For this,
colon microbiota were autoclaved for 30 min
(121°C, 1 bar overpressure). Incubation of
PAH standard compounds in stomach, small
intestine, and colon digests occurred at a con-
centration of 20 µmol/L. This concentration is
normally not encountered in the GI tract but
gave us more possibilities to study microbial
PAH metabolism in depth. GI digestion
experiments on soil samples were performed as
previously described (Van de Wiele et al.
2004b) to simulate a hypothetical soil inges-
tion of 5 g/day by pica-afflicted children
(stomach, 40 mL; small intestine, 60 mL;
colon, 100 mL). To avoid photocatalytic
effects, all digestions were performed in amber
flasks. After the respective incubations, sam-
ples were centrifuged at 3,000g for 10 min to
remove most of the particulates and biomass.
The supernatants were then stored at –20°C
before analysis.
Sample treatment. PAH parent compo-
nents and PAH metabolites were extracted
from the digests by performing a liquid/liquid
extraction in which the digest and ethyl
acetate were mixed in a 1:1 ratio. The ethyl
acetate fraction was then put in a rotary evap-
orator to remove most of the solvent. The
remainder of the solvent was removed under a
gentle stream of nitrogen gas and finally
replaced by dimethyl sulfoxide, which is suit-
able for use in bioassay tests. For chemical
analysis of the samples using LC-MS, sample
aliquots were subjected to solid-phase extrac-
tion using PrepSep C18 (250 mg; Fisher
Scientific, Edmonton, Alberta, Canada).
Hydroxy-PAHs were eluted with methanol.
PAH conjugate analysis. To check whether
conjugated PAH metabolites were formed in
the different digests, samples were also incu-
bated in the presence of β-glucuronidase and
aryl sulfatase, both obtained from Sigma-
Aldrich. After the PAH parent compounds had
been incubated in SHIME suspension, a 1 mL
aliquot of these samples was diluted in 1 mL
0.1 M acetate buffer, and the pH was adjusted
to 5 with sodium hydroxide. A volume of
400 µL β-glucuronidase (100 U/mL) and
250 µL aryl sulfatase (60 U/mL) was added,
and the mixture was incubated for 6 hr at
37°C to hydrolyze the PAH conjugates.
Bioassays. For the bioassays, we used a
modified protocol from De Boever et al.
(2001) that was based on the protocol devel-
oped by Routledge and Sumpter (1996) for the
yeast estrogen bioassay and Miller (1997) for
the yeast Ah bioassay. Brieﬂy, these researchers
transformed Saccharomyces cerevisiae with the
human Ah receptor gene and the human ER-α
gene, together with expression plasmids con-
taining responsive elements and the lacZ
reporter gene (encoding the enzyme β-galacto-
sidase). The expression of β-galactosidase is
triggered by test chemicals, which upon bind-
ing to the respective receptors induce the con-
formational change necessary for binding of
the receptor/ligand dimer to the responsive ele-
ments. This β-galactosidase activity is quanti-
fied at 540 nm by the conversion of the
chromogenic substance chlorophenol red–
β-D-galactopyranoside into chlorophenol red.
The bioassay response is expressed as the
absorbance at 540 nm divided by the optical
density at 630 nm [(A540/A630)net]. Positive
signals in the Ah receptor assay were typically
expressed as percentage equivalence to 200 nM
benzo(a)pyrene, which arbitrarily corresponded
to a bioassay response of 100%. Similarly,
estrogenic activity of the samples was expressed
as percentage equivalence to 6.96 nM 17α-
ethynyl estradiol (EE2), which elicited a 100%
response in the ER bioassay (De Boever et al.
2001). To make sure that background signals
from GI suspensions of soil or food matrices
did not interfere with the detection of estro-
genic signals in the bioassays, corrections were
made in a set of negative control experiments
by subtracting the response of a PAH-
containing digest from that from a blank digest
without PAHs (see Supplemental Material
available online at http://ehp.niehs.nih.gov/
docs/2004/7259/supplemental.pdf). The bio-
assays were performed in 96-well plates in
which 10 µL of the test compounds was tested
and incubated with 240 µL of the genetically
modified yeast (optical density, 0.25 at 610
nm). Serial dilutions of the test compounds
were made in dimethyl sulfoxide, which
allowed generation of dose–response curves for
doses (ordinate) versus activity (abscissa). The
data were ﬁtted by a four-parametric logistic
model using the Marquardt-Levenberg algo-
rithm (Sigmaplot 4.0; SPSS Inc., Chicago, IL,
USA) (De Boever et al. 2001).
PAH analysis. Sample treatment for and
determination of PAHs were performed 
by the Environmental Research Centre
(Erembodegem, Belgium). Brieﬂy, PAHs from
pellets were extracted by a 1:1 acetone:hexane
mixture using an ASE 200 accelerated solvent
extractor (Dionex, Sunnyvale, CA, USA).
PAHs from supernatants were extracted with
dichloromethane. Analysis of the PAH content
in the extracts was performed according to a
standardized method [U.S. Environmental
Protection Agency (EPA) method 8270 (U.S.
EPA 1996)] by gas chromatography coupled
with mass spectrometry (GC-MS). We used a
quadrupole mass spectrometer (Trace-MS;
Fisons/Thermoquest, Antwerp, Belgium). The
detection limit for the different PAH compo-
nents was 0.2 µg/L, and the quantification
limit was 0.4 µg/L. The extraction efﬁciency of
the sample preparation step before PAH analy-
sis was between 80 and 110%, as determined
with reference soil CRM535 (Environmental
Research Center, Erembodegem, Belgium).
LC-MS analysis. We performed LC-MS
analysis of the samples for hydroxy-PAHs as
previously described (Van de Wiele et al.
(2004a). The identity of hydroxy-PAH
metabolites in the samples was conﬁrmed by
using synthetic standards of these metabolites
and comparing the HPLC profiles from the
colon digests with those from the standards.
Briefly, all samples for LC-MS analysis were
subjected to solid-phase extraction using
PrepSep C18 columns (250 mg). Sample 
volumes of 5 mL were loaded on the columns
and washed with 10 mL Milli-Q water; the
Article | Estrogenic PAH metabolites from colon microbiota
Environmental Health Perspectives • VOLUME 113 | NUMBER 1 | January 2005 7
Figure 1. Schematic representation of SHIME. Vessels 1–5 simulate conditions from the stomach, small
intestine, colon ascendens, colon transversum, and colon descendens, respectively.
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N2target analytes were then eluted with 10 mL
methanol. Aliquots (1 mL) were subsampled
and stored in amber vials at 4°C before LC-
MS analysis. HPLC analysis was performed
using a Waters 2695 separation module
(Waters, Milford, MA, USA). The selected
column was a 2.1 mm × 100 mm, 3.5 µm
particle size, Waters XTerra MS C18 column,
which was kept at a constant temperature of
26°C. The binary eluent system consisted of
methanol:water 90:10 (vol/vol; eluent A) and
methanol:water 10:90 (vol/vol; eluent B). MS
analysis was performed with a Quattro Ultima
Mass spectrometer (Micromass Technologies,
Manchester, UK) that was equipped with an
electrospray interface operating in the negative
ion mode. Instrumental control and data
acquisition were performed with MassLynx
software version 3.5 (MicroMass Ltd.,
Manchester, UK). The electrospray ionization
source was operated at 90°C, a desolvation
temperature of 200°C, a cone voltage of 61 V,
and a capillary voltage of 2.74 kV. Nitrogen
gas served as the cone gas (flow rate of
159 L/hr), desolvation gas (490 L/hr), and
nebulizer gas (set to maximum). The detector
multiplier voltage was set to 650 V. We used
selected ion monitoring for quantitative analy-
sis monitoring the (M – H)– of m/z for the
hydroxy-PAHs.
Results and Discussion
Because of their moderate-to-high degree of
aromaticity, we expected pure solutions of
naphthalene, phenanthrene, pyrene, and
benzo(a)pyrene to test positive in the Ah
bioassay. Naphthalene (200 nM) displayed
0.4% benzo(a)pyrene equivalence, whereas
200 nM phenanthrene and 200 nM pyrene
displayed 15.1 and 48.2% benzo(a)pyrene
equivalence, respectively. PAH compounds
are not estrogenic, and indeed, up to 16 µM
of the four pure PAHs did not induce an
estrogenic response in the estrogen bioassay.
Similarly, separate stomach and small intes-
tine digests of the four PAHs did not show a
significant estrogen response (Figure 2). In
contrast, PAHs from colon digests became
estrogenic. Conversion of the percent EE2
equivalence values, shown in Figure 2, to
equivalent EE2 concentrations is as follows: for
colon digests of 62.5 nM pyrene, 2.70 nM
EE2 equivalence; for phenanthrene, 2.14 nM
EE2 equivalence; for benzo(a)pyrene, 1.48 nM
EE2 equivalence; and for naphthalene,
0.31 nM EE2 equivalence. This PAH bio-
activation was only evident in colon digestion.
This shows the selectivity of colon digestion
toward an increase in estrogenicity, whereas no
increased Ah response was detected, compared
with stomach or small intestine digests. To
make sure that the observed effects were not
coming from the matrix background of the
colon interacting with PAHs, we incubated
PAHs in a heat-inactivated colon suspension.
The removal of microbial activity markedly
reduced the increase in estrogenic activity
(Figure 2). This ﬁnding indicates that the risk
for PAH bioactivation along the GI tract is
not exclusively associated with human bio-
transformation enzymes from the enterocytes
in the small intestine epithelium and colono-
cytes in the large intestine epithelium (Autrup
et al. 1978; De Kok and van Maanen 2000;
Doherty and Charman 2002), but that colon
microbiota can also bioactivate PAHs.
We then evaluated the signiﬁcance of this
process using lower, more realistic concentra-
tions obtained from soil from a former urban
playground contaminated with 49 ± 1.5 mg
PAHs per kilogram soil (dry weight) by years
of atmospheric deposition. Pica-afﬂicted chil-
dren form the largest risk group for soil inges-
tion because of their unusual hand–mouth
behavior and low body weight. Hence, we
simulated the GI tract of a pica child, hypo-
thetically ingesting 5 g soil/day. GC-MS analy-
sis previously showed that the released PAH
fraction from the soil matrix was highest in the
stomach digest (18 ± 5.3 µg/L), followed by
the small intestine digest (3 ± 1.1 µg/L) and
the colon digest (2 ± 0.3 µg/L) (Van de Wiele
et al. 2004b). This corresponded to a maximal
Ah bioassay response for the stomach digest of
41 ± 2.9% benzo(a)pyrene equivalence; the
small intestine, 27 ± 1.4%; and the colon, 22 ±
2.6% (Figure 3). Based on the role of the
human Ah receptor in the toxicity of speciﬁc
aromatic hydrocarbons, these ﬁndings would
normally indicate that the colon digest repre-
sents the lowest risk for PAH bioactivation.
Surprisingly, the trend in estrogenic activity
was the inverse of observed PAH release or Ah
bioassay response. Similar to the estrogen
bioassay results on pure PAHs, there was negli-
gible induction of estrogenic activity in the
stomach (0.6%) and small intestine (2.0%)
digestion (Figure 4). However, an average
value of 20.1 ± 0.84% EE2 equivalence was
observed in a colon digestion of the contami-
nated soil (Figure 4). We infer that the PAH
bioactivation potency from colon microbiota
also occurs at lower and relevant concentra-
tions for human exposure and that the pres-
ence of soil does not eliminate this potency.
Soil organic matter and nutritional ﬁbers
are known to lower the fraction of a contami-
nant that can be absorbed by the intestine
(O’Neill et al. 1991; Oomen et al. 2000; van
Schooten et al. 1990). This would theoretically
lower the risk from ingested contaminants
because bioactivation by human biotransfor-
mation enzymes will be reduced because of a
lower bioavailability. To test this hypothesis,
we compared the estrogenicity from colon-
incubated PAHs in the presence and absence
of soil by calculating the bioactivation potency
of the digests as estrogenicity/aromaticity. We
divided—at equimolar concentrations—the
percent EE2 equivalence of the different digests
by their respective percent benzo(a)pyrene
equivalence. At equimolar concentrations of
8.03 nmol PAH/L, this ratio was 0.93 for
naphthalene, 2.16 for phenanthrene, 0.98 for
pyrene, and 0.12 for benzo(a)pyrene, whereas
the colon digest of the PAH-contaminated
soil gave a ratio of 0.88, the same order of
magnitude as the ratios for pure PAH com-
pounds and one order of magnitude higher
than the ratios for the stomach soil digest
(0.016) or small intestine soil digest (0.077).
Article | Van de Wiele et al.
8 VOLUME 113 | NUMBER 1 | January 2005 • Environmental Health Perspectives
Figure 2. Estrogen response (mean ± SD) of naph-
thalene, phenanthrene, pyrene, and benzo(a)pyrene
(62.5 nmol/L) incubated in stomach, small intes-
tine, and colon digests and in digests with inacti-
vated colon microbiota. Values are means of four
replicates.
*None of the stomach digestions gave a significant
response in the estrogen bioassay.
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Figure 3. Dose–response curve of stomach, small
intestine, and colon digests of PAH-contaminated
playground soil in the Ah receptor yeast bioassay,
expressed as percent benzo(a)pyrene equivalence
in function of released PAH concentrations in the
respective digests. Values are means of four repli-
cates; error bars represent SD. 
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Figure 4. Released concentrations of PAHs and
estrogen response in stomach, small intestine, and
large intestine digests incubated with PAH-conta-
minated soil samples. Values are means of four
replicates; error bars represent SD. 
25
20
15
10
5
0
P
A
H
 
r
e
l
e
a
s
e
d
(
%
 
E
E
2
 
e
q
u
i
v
a
l
e
n
c
e
)
Stomach Colon Small intestine
PAH release
EstrogenicityThese findings provide further evidence that
the presence of a soil matrix does not elimi-
nate the PAH bioactivation by colon micro-
biota and that the estrogenic potency of
soil-derived PAHs does not significantly
decrease if compared with pure PAHs.
PAH metabolites that typically have estro-
genic properties are hydroxylated derivatives
because of their structural similarity to natural
estrogens (Fertuck et al. 2001; Hirose et al.
2001). Hence, in the next step of the research,
we screened with LC-MS for the presence of
hydroxy-PAHs by analyzing the respective
colon digests of 20 µmol/L pure PAH com-
pounds. The identity of PAH metabolites was
confirmed by comparing the HPLC profiles
and MS spectra of the colon digests with those
from chromatographic synthetic standards of
several hydroxy-PAHs. The developed protocol
had reasonably low detection limits for 1-OH
naphthalene, 9-OH phenanthrene, 1-OH
pyrene, and 7-OH benzo(a)pyrene (Table 1)
(Van de Wiele et al. 2004a). No hydroxy-PAHs
were detected upon stomach or small intestine
incubations. From all colon digests, only the
pyrene digest tested positive for a hydroxy-PAH
metabolite, with 1-OH pyrene at a concentra-
tion of 2.5 µg/L (Table 1). Glucuronidated or
sulfated PAH conjugates are also typical bio-
transformation products from eukaryotic
organisms (Cajthaml et al. 2002). Because the
concentration of fungi and yeasts in the colon
suspension amounted to 4.3 ± 0.6 log colony
forming units (CFU)/mL, we tested whether
PAH conjugates were present in colon digests
of pure PAH compounds. Glucuronidase and
arylsulfatase typically cleave off glucuronic acid
or sulfate groups from conjugated PAHs,
regenerating the hydroxy-PAH metabolites
(Cajthaml et al. 2002). After incubating the
extracts of the colon digests in the presence of
glucuronidase (100 U/mL) and arylsulfatase
(60 U/mL) for 6 hr at 37°C, we found higher
concentrations of 1-OH pyrene (4.4 µg/L) and
a new metabolite, 7-OH benzo(a)pyrene
(1.9 µg/L). No hydroxy-PAHs were retrieved
from inactivated colon samples. Although
other hydroxy-PAHs may have formed than
those tested during LC-MS analysis, these ana-
lytical data show that PAH bioactivation by
colon microbiota may result from hydroxy-
PAH metabolites.
The formation of hydroxy-PAH metabo-
lites and especially the increased estrogenicity
by human colon microbiota bring up two
questions: are the observed transformations
plausible for the in vivo human GI tract, and
to what extent can bioactive PAH metabo-
lites contribute to the total risk from oral
PAH exposure? To answer the ﬁrst question,
literature shows that resident gut microbiota
may influence xenobiotic metabolism from
the intestinal epithelium (Hooper et al. 2001).
Additionally, microbial glucuronidase activity
in the intestine sometimes cleaves off glu-
curonic acid groups from excreted human con-
jugated metabolites, thus regenerating the
more bioactive hydroxylated intermediates
(Aura et al. 2002). These reports describe indi-
rect effects of intestinal microbiota toward
xenobiotic metabolism. However, our ﬁndings
indicate a direct metabolism effect of human
colon microbiota toward PAH parent com-
pounds, because the in vitro approach used in
the present study eliminated possible interfer-
ences by intestinal epithelium enzymes. The
observed biotransformation and bioactivation
reactions originate from a microbial commu-
nity that resembles that of the in vivo intestinal
lumen both in composition and in metabolic
activity. Rather than containing the less active
microbiota from fecal matter, the microbial
community from the used in vitro method is
more representative of the different parts of the
human colon (Molly et al. 1993).
As suggested by the LC-MS results, the
colon microbiota formed hydroxy-PAH
metabolites, which may seem unlikely because
this oxidative step would occur in an anaero-
bic environment, as shown by redox potential
values from the colon suspension, which var-
ied between –180 mV and –230 mV. These
values are well within the range of –145 mV
to –250 mV reported for the colon in vivo
(Bowler et al. 2001; Chourasia and Jain
2003). Yet, oxidative reactions by intestinal
bacteria from humans, mice, and rats have
been described for the conversion of 2-amino-
3-methylimidazo[4,5-f ]quinoline to its report-
edly mutagenic 7-keto derivative (Rumney
et al. 1993). Additionally, Enterococcus faecalis
even performs aromatic hydroxylation reac-
tions in the intestine in vivo (Huycke and
Moore 2002). It is therefore not unlikely that
intestinal microbiota may hydroxylate PAHs,
also given the fact that anaerobic PAH
hydroxylation has been reported by microor-
ganisms, albeit in sediments (Karthikeyan and
Bhandari 2001). These studies on oxidative
reactions by intestinal microbiota and anaero-
bic PAH biotransformations may thus sup-
port our ﬁndings, which need further study to
identify which microorganisms bioactivate
PAHs.
To answer the second question concerning
the contribution of the observed effects to the
total risk from PAH ingestion, further research
is warranted. Yet, microbial PAH bioactivation
to estrogenic metabolites may constitute an
increased health risk when the human body is
orally exposed to contaminated soils. Human
colon epithelium is 20% more permeable to
17β-estradiol than is the human small intes-
tine epithelium (van der Bijl and van Eyk
2003) and also has a higher permeability to
hydrophobic compounds in general (Ungell
et al. 1998). PAH metabolites with structures
resembling steroidal hormones may thus
exhibit weak estrogenic or antiestrogenic activ-
ity in vivo (Ariese et al. 2001). Because PAHs
that reach the colon will be biotransformed by
colon microbiota, we conclude that, in the
in vivo situation, the colonic epithelium—
which has ERs—may be subjected to hazardous
effects from microbial PAH metabolites. The
equivalent EE2 response of 20% for the
colon-incubated environmental sample
(Figure 4) indicates that the observed activa-
tion of the human ER is significant. Still, it
must be kept in mind that a positive response
in ER-reporter gene assays such as that from
the present study does not necessarily predict
endogenous transcription (Gozgit et al. 2004).
Gozgit et al. (2004) noted that several PAHs
induced activity in ER-reporter gene assays
but that these PAHs did not up-regulate estro-
gen-responsive genes. The authors concluded
that ER-reporter gene assays may detect con-
centrations of toxicants that are not physiolog-
ically active. In light of these recent ﬁndings,
the estrogenic response from microbial PAH
bioactivation in this study needs careful inter-
pretation. However, the finding of 1-OH
pyrene and 7-OH benzo(a)pyrene as metabo-
lites from human colon microbiota is some-
thing that is not anticipated from current
scientiﬁc knowledge or risk assessment studies.
Comparison of our findings from active to
those from inactivated colon microbiota
shows that the microbial bioactivation
potency is a factor of 12 higher than would be
currently expected in risk calculations.
Moreover, the time during which bioactive
hydroxy-PAHs could react with colonocytes is
also considerably longer (up to 72 hr) than
the residence time in human enterocytes or
hepatocytes (6 hr maximum). Additionally, if
taken up by colonocytes, the hydroxy-PAHs
are typical metabolites that are more easily
metabolized by human biotransformation
enzymes to, for example, potent carcinogens
such as benzo(a)pyrene-r7,t8-dihydrodiol-
t9,10-epoxide (Kim et al. 1998). Clearly, these
literature reports on human PAH metabolism
and our findings of PAH bioactivation by
colon microbiota indicate the importance of
conducting future work in which the relative
importance of the human bioactivation
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Table 1. Limits of detection (LODs) of hydroxy-PAHs
obtained with LC-MS analysis, concentrations of
the hydroxy-PAHs in the colon digest, and concen-
trations of the hydroxy-PAHs in the deconjugated
colon digest.
Colon Colon digest
LOD digest deconjugated
Hydroxy-PAH (µg/L) (µg/L) (µg/L)
1-OH naphthalene 7.33 ND ND
9-OH phenanthrene 0.47 ND ND
1-OH pyrene 0.24 2.5 4.4
7-OH benzo(a)pyrene 0.95 ND 1.9
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10 VOLUME 113 | NUMBER 1 | January 2005 • Environmental Health Perspectives
processes versus the microbial bioactivation
processes should be compared.
Conclusion
Our results reveal that human colon micro-
biota can directly bioactivate PAHs, a potency
that has not been reported before. As indi-
cated by the analysis of a PAH-contaminated
environmental sample, we also show that the
presence of soil does not eliminate this micro-
bial bioactivation potency. We therefore con-
clude that risk calculations that are based solely
on human biotransformation enzymes may
underestimate the risk from ingested aromatic
contaminants because it does not consider the
bioactivation processes described here.
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